Literature DB >> 29980273

Relation of Subclinical Hypothyroidism is Associated With Cardiovascular Events and All-Cause Mortality in Adults With High Cardiovascular Risk.

Shinje Moon1, Sung Hye Kong2, Hoon Sung Choi3, Yul Hwangbo4, Moon-Kyu Lee5, Jae Hoon Moon6, Hak Chul Jang6, Nam Han Cho7, Young Joo Park8.   

Abstract

The aim of this study was to determine the association between subclinical hypothyroidism and cardiovascular (CVD) events, and mortality using the atherosclerotic CVD risk score. We carried out an observational study in a prospective cohort that was followed up for 12 years. The study included 3,021 participants aged ≥ 40 years at baseline from the Ansung cohort, part of the Korean Genome and Epidemiology Study. Cox regression models were constructed to evaluate the hazards ratio (HR) and 95% confidence interval (CI) for all-cause mortality and CVD events in groups classified according to thyroid status. Subgroup analysis was performed with a cut-off age of 65 years or 7.5% of the 10-year atherosclerotic CVD risk score. The subclinical hypothyroidism group in the highest quartile of thyroid-stimulating hormone (>6.57 mIU/L) had a significantly increased risk of all-cause mortality (HR 2.12, 95% CI 1.27 to 3.56) and CVD events (HR 1.92, 95% CI 1.21 to 3.04) compared with euthyroid participants. Subgroup analysis by CVD risk revealed that participants with high CVD risk only had a high risk of all-cause mortality (HR 2.18, 95% CI 1.22 to 3.87) and CVD events (HR 2.42, 95% CI 1.35 to 4.33). Further analysis showed that participants aged <65 years with high CVD risk had the highest risk of all-cause mortality (HR 3.50, 95% CI 1.50 to 8.16) and CVD events (HR 3.37, 95% CI 1.46 to 9.57). Our results demonstrated that high thyroid-stimulating hormone levels were associated with a greater risk of mortality and new CVD risks, particularly among subjects with high CVD risk.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29980273     DOI: 10.1016/j.amjcard.2018.03.371

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal.

Authors:  Benjamin Van Tassell; George F Wohlford; Joyce D Linderman; Sheila Smith; Sahzene Yavuz; Frank Pucino; Francesco S Celi
Journal:  Thyroid       Date:  2019-09-12       Impact factor: 6.568

2.  Subclinical Hypothyroidism Affects the Long-Term Outcomes of Patients Who Undergo Coronary Artery Bypass Grafting Surgery but Not Heart Valve Surgery.

Authors:  Hana Kim; Sung Hye Kong; Jae Hoon Moon; Sang Yoon Kim; Kay-Hyun Park; Jun Sung Kim; Joong Haeng Choh; Young Joo Park; Cheong Lim
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

3.  Unknown Subclinical Hypothyroidism and In-Hospital Outcomes and Short- and Long-Term All-Cause Mortality among ST Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Elena Izkhakov; David Zahler; Keren-Lee Rozenfeld; Dor Ravid; Shmuel Banai; Yan Topilsky; Naftali Stern; Yona Greenman; Yacov Shacham
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

4.  Thyroid Function across the Lifespan: Do Age-Related Changes Matter?

Authors:  John P Walsh
Journal:  Endocrinol Metab (Seoul)       Date:  2022-04-14

Review 5.  Levothyroxine for the Treatment of Subclinical Hypothyroidism and Cardiovascular Disease.

Authors:  Laura Y Sue; Angela M Leung
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-21       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.